Generic Adderall XR APPROVAL Means PRESSURE for Shire and 4 More Stock Insights
MGM Resorts International (NYSE:MGM) margin expansion is important because of the compelling nature of its risk/reward and greater operational focus, says Deutsche Bank. Shares have a Buy rating and a $16 price target.
Apple Inc. (NASDAQ:AAPL): Because of weaker demand an inventory reductions, Goldman has lowered forecasts for global Handsets and Smartphones. The firm dropped its predictions for 2012 handset unit growth from 10% to 4% and smartphone growths from 42% to 38%.
Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): According to Leerink, it was not surprising that Teva was favored in the Copaxone patent trial, but some overhang which could have been influencing some investors out of the stock. It has been noted by the firm that the weekend also saw Actavis’ generic form of AXR approved, a small negative for Teva. The firm maintains an Outperform rating on the shares.
Shire plc (NASDAQ:SHPGY): As a result of ANDA’s approval for Actavis’ generic form of Adderall XR, Leerink predicts pressure for Shire shares, but sees the weakness as a buying point. Leerink views Adderall XR as highly profitable for the company, but because of the possibility of Vyvanse’s long-term revenue growth, the firm keeps an Outperform rating on shares.
Kirby Corporation (NYSE:KEX): Jefferies states that half of Kirby’s guidance reduction was a result of one-off charges or occurrences in Q1 or Q2. According to the firm, reduction removes an overhand. The firm maintains a Buy rating, but the price target was lowered from $77 to $70 on the stock.
Don’t Miss: Will Facebook’s New Ads Succeed or Fail?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.